Our 29th annual Advances in Autism Conference will be hosted on Tuesday, May 6, 2025 at The New York Academy of Medicine.
The focus of the 2025 Advances in Autism Conference is Precision Therapeutics in Profound Autism.
About
Established in 1996, the conference brings together academic, parent and community groups to participate in thoughtful and informative presentations. The goals of the event are to discuss recent advances in autism – the causes, symptoms, and current and future treatments.
Reserve Tickets and Sponsorships Soon!
Joseph D. Buxbaum, PhD, MSc - Developing Disease-Modifying Therapeutics in Profound Autism
Director, Seaver Autism Center
Matthew Disney, PhD - Targeting RNA Structural Elements to enhance ASD Gene Expression
Institute Professor & Chair, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology
Fred Etoc, PhD - Drug Screening for Rare Neurodevelopmental Disorders Using Brain Micro-Tissues
Chief Scientific Officer, Rumi Scientific
Alex Kolevzon, MD - Developing Treatments in Phelan-McDermid Syndrome: Past, Present, and Future
Clinical Director, Seaver Autism Center
Professor, Psychiatry and Pediatrics; Director, Child and Adolescent Psychiatry
Mount Sinai Health System
Paige Siper, PhD - Measuring Outcomes in Profound Autism
Chief Psychologist, Seaver Autism Center, Associate Professor of Psychiatry
Pilar Trelles, MD - Maximizing Impact in Autism Research Through Inclusive Community Partnerships
Associate Chief Psychiatry, Outpatient Psychiatry Service, Boston Children's Hospital
International studies led by the Director of the Seaver Autism Center, Joseph D. Buxbaum, PhD, MSc and colleagues, have identified more than 200 genes that, if changed, strongly contribute to autism. These discoveries also show that at least 25% of individuals with profound autism have genetic mutations.
Clinical researchers are now shifting their focus on treatments for autism. Rather than treating all autism as a single entity, we can now begin to look at genetically determined subtypes of autism and consider treatments that are tailored to the genetic subtype. This approach, called precision therapeutics, has revolutionized cancer treatment, and will revolutionize the treatment of profound autism.
Attend the conference to learn how researchers are identifying genetic mutations in autism, how the mutations lead to biologically-determined subtypes of autism, and how preclinical and clinical research are developing and testing new treatments for these subtypes. The interactions between academic scientists, families and advocacy groups, and industry partners will also be discussed, as precision therapeutics requires input from all these groups.